OncoResponse Alternatives & Competitors
12 companies similar to OncoResponse — Interrogating for Cures
Companies similar to OncoResponse
Surface Oncology Inc.
#lifeunderthesurface #BBJBestPlacesToWork2023,2022,2021 #BostonGlobeTopPlacesToWork2023,2...
Cambridge, United States
Merus N.V.
Merus was acquired by Genmab. To see what’s new, visit Genmab.
Utrecht, The Netherlands
Marseille, France
Imugene Limited
Bringing Effective New Treatments And Options To Patients Who Need Them
Australia
Rival Readout
Competing with OncoResponse? We do this properly.
10 rivals, 90 days of dated moves, ranked by what matters and sourced, in 7 business days.
Aulos Bioscience
We’re revolutionizing #cancercare through #IL2 therapeutics designed to direct the #immune...
Larkspur, United States
NextPoint Therapeutics, Inc.
Launching a new world of precision therapeutics through its leading scientific work on th...
FogPharma
Until everything is druggable.
Cambridge, United States
Apexigen
Creating Transformative Immunotherapies for Patients with Cancer
San Carlos, United States
Oxford BioTherapeutics
Redefining the cancer-immune synapse for novel immune checkpoint mechanisms
Oxford, United Kingdom
MetiMedi Co., Ltd.
MetiMedi is developing a first-in-class oral immunotherapeutic small molecule in Phase 2 f...
Korea South
Adagene
Redefining the design and discovery of therapeutic antibodies
Neobe Therapeutics
Engineering live biotherapeutics to disrupt the tumour microenvironment and enable immunot...
London, United Kingdom
About OncoResponse
OncoResponse, founded in 2016, is an innovative player in the immuno-oncology biotech sector. This biopharma company is particularly notable for its strategic collaboration with the MD Anderson Cancer Center, which amplifies its capabilities in treating cancer. Utilizing a proprietary B-cell discovery platform, OncoRes...
Development of novel cancer immunotherapies, Discovery of human antibodies, Partnering with collaborators in immuno-oncology, Preclinical studies
Biopharmaceutical companies, Oncology researchers, Cancer patients, Clinical study collaborators
Immuno-oncology, Biotech, Cancer Immunotherapy, Antibody Platform, B-cell Discovery, Tumor Microenvironment, Monoclonal Antibodies, Immune Activation, TME Immunosuppression, Elite Cancer Responders, Novel Therapeutics, Myeloid Biology, Clinical Trials, Human Antibodies
B2B, B2D, Platform
Licensing, Performance Based, Service Fee
Frequently Asked Questions
From the desk
Mapping a market? Start with a Rival Readout.
In 7 business days we read 10 rivals around OncoResponse: 90 days of dated moves, ranked by what matters to you, each with its source. Fully credited if you continue.
Compiled from the BounceWatch company index. We last looked at OncoResponse on 9 Jun 2026. The 12 companies listed here were last checked between 11 Sep 2024 and 15 Jun 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.
